GSK and Imperial

The Fleming Initiative, led by Imperial College London, is a global effort to combat the growing threat of antimicrobial resistance (AMR), which could cause an estimated 10 million deaths annually by 2050.

GSK is a pivotal founding partner, having committed a substantial investment of $45 million. This partnership is a key part of GSK's strategy to address major global health challenges and underscores its role as a leader in life sciences. The funding enables the Initiative to leverage technology and data, particularly through the use of AI, to accelerate the discovery of new drugs and diagnostics, improve surveillance, and study transmission of drug-resistant infections. 

The Centre, located at the historic St Mary’s Hospital - where penicillin was discovered by Nobel Prize winner Sir Alexander Fleming - will serve as a hub for scientists, policymakers, and industry to work together on solutions.  

This convergence of expertise is crucial, as AMR is a complex problem that requires an interdisciplinary approach. For other companies, opportunities to contribute range from joining existing collaborations to establishing multi-year, flagship research Centres.  

Imperial's Enterprise team facilitates these collaborations, from pitching and intellectual property negotiations to the implementation and management of research projects, ensuring that commercial investment translates into tangible societal benefit.